Natural Products as Promising Therapeutics for Treatment of Influenza Disease
No Thumbnail
Authors
Senćanski, Milan V.Radošević, Draginja
Perović, Vladimir R.
Gemović, Branislava S.
Stanojevic, Maja
Veljković, Nevena V.
Glišić, Sanja
Article (Published version)
Metadata
Show full item recordAbstract
The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the p...ossible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Keywords:
Influenza disease / natural compounds / therapeutic targets / drug development / drug repurposing / influenza hemagglutinin inhibitors / influenza NS1 inhibitors / influenza polymerase inhibitorsSource:
Current Pharmaceutical Design, 2015, 21, 38, 5573-5588Funding / projects:
- Application of the EIIP/ISM bioinformatics platform in discovery of novel therapeutic targets and potential therapeutic molecules (RS-MESTD-Basic Research (BR or ON)-173001)
DOI: 10.2174/1381612821666151002113426
ISSN: 1381-6128; 1873-4286
PubMed: 26429712
WoS: 000364518900009
Scopus: 2-s2.0-84957056707
Collections
Institution/Community
VinčaTY - JOUR AU - Senćanski, Milan V. AU - Radošević, Draginja AU - Perović, Vladimir R. AU - Gemović, Branislava S. AU - Stanojevic, Maja AU - Veljković, Nevena V. AU - Glišić, Sanja PY - 2015 UR - https://vinar.vin.bg.ac.rs/handle/123456789/806 AB - The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics. T2 - Current Pharmaceutical Design T1 - Natural Products as Promising Therapeutics for Treatment of Influenza Disease VL - 21 IS - 38 SP - 5573 EP - 5588 DO - 10.2174/1381612821666151002113426 ER -
@article{ author = "Senćanski, Milan V. and Radošević, Draginja and Perović, Vladimir R. and Gemović, Branislava S. and Stanojevic, Maja and Veljković, Nevena V. and Glišić, Sanja", year = "2015", abstract = "The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.", journal = "Current Pharmaceutical Design", title = "Natural Products as Promising Therapeutics for Treatment of Influenza Disease", volume = "21", number = "38", pages = "5573-5588", doi = "10.2174/1381612821666151002113426" }
Senćanski, M. V., Radošević, D., Perović, V. R., Gemović, B. S., Stanojevic, M., Veljković, N. V.,& Glišić, S.. (2015). Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design, 21(38), 5573-5588. https://doi.org/10.2174/1381612821666151002113426
Senćanski MV, Radošević D, Perović VR, Gemović BS, Stanojevic M, Veljković NV, Glišić S. Natural Products as Promising Therapeutics for Treatment of Influenza Disease. in Current Pharmaceutical Design. 2015;21(38):5573-5588. doi:10.2174/1381612821666151002113426 .
Senćanski, Milan V., Radošević, Draginja, Perović, Vladimir R., Gemović, Branislava S., Stanojevic, Maja, Veljković, Nevena V., Glišić, Sanja, "Natural Products as Promising Therapeutics for Treatment of Influenza Disease" in Current Pharmaceutical Design, 21, no. 38 (2015):5573-5588, https://doi.org/10.2174/1381612821666151002113426 . .
Related items
Showing items related by title, author, creator and subject.
-
Conserved HA-peptide NG34 formulated in pCMV-CTLA4-Ig reduces viral shedding in pigs after a heterosubtypic influenza virus SwH3N2 challenge
Sistere-Oro, Marta; Vergara-Alert, Julia; Stratmann, Thomas; Lopez-Serrano, Sergi; Pina-Pedrero, Sonia; Cordoba, Lorena; Perez-Maillo, Monica; Pleguezuelos, Patricia; Vidal, Enric; Veljković, Veljko; Segalés, Joaquim; Nielsen, Jens Peter; Fomsgaard, Anders; Darji, Ayub; Huber, Victor C. (PLOS One, 2019) -
Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism
Veljković, Veljko; Glišić, Sanja; Veljković, Nevena V.; Bojić, Tijana; Dietrich, Ursula; Perović, Vladimir R.; Colombatti, Alfonso (Vaccine, 2014) -
Novel algorithm for phylogenetic analysis of proteins: application to analysis of the evolution of H5N1 influenza viruses
Perović, Vladimir R. (Journal of Mathematical Chemistry, 2013)